Novo Nordisk A/S

New York Stock Exchange
Back to all articles
Very Bearish -75

Novo Nordisk Cuts Wegovy Prices in Half While Its Stock Sits Near a 52-Week Low

AI-generated analysis

📉 Novo Nordisk shares dropped 22% in the past week and 56% over the past year, trading near a 52-week low of approximately $39.63.

🔬 The REDEFINE-4 trial showed CagriSema produced 23% average body weight loss versus 25.5% for Eli Lilly's Zepbound, marking a competitive blow.

📉 JPMorgan downgraded Novo from Overweight to Neutral and slashed CagriSema forecasts by 40-63% for the period through 2030.

💰 Novo announced it will cut list prices for Ozempic, Rybelsus, and Wegovy to $675/month effective January 1, 2027.

📉 The price cut validates Novo's previously flagged guidance of -5% to -13% sales growth for 2026 due to pricing pressure.

🇪🇺 The EU recently approved a 7.2 mg higher-dose Wegovy showing 20.7% average weight loss versus 17.5% for the standard dose.

💊 Early scripts for the oral Wegovy pill formulation reached roughly 48,000 in Week 7, up 12% week-over-week.

📊 Analysts now debate whether Novo's valuation reflects a durable repricing of its competitive position or a temporary overreaction.

🗳️ The Annual General Meeting is scheduled for March 26 where new board members will be voted on.

Bullish Signals
  • The EU recently approved a 7.2 mg higher-dose Wegovy showing 20.7% average weight loss versus 17.5% for the standard dose, demonstrating product efficacy.
  • Early scripts for the oral Wegovy pill formulation reached roughly 48,000 in Week 7, up 12% week-over-week, indicating strong initial uptake.
Risk Factors
  • The REDEFINE-4 trial showed CagriSema produced 23% average body weight loss versus 25.5% for Eli Lilly's Zepbound, a sizable blow to its pipeline.
  • JPMorgan downgraded Novo from Overweight to Neutral and slashed CagriSema forecasts by 40-63% for 2027-2030 following the trial miss.
  • Deutsche Bank and Kepler Cheuvreux lowered their ratings, with the 12-month average price target now sitting at $54.25.
  • Novo announced it will slash list prices for Ozempic, Rybelsus, and Wegovy to $675/month effective January 1, 2027, down from Wegovy's current price of roughly $1,349/month.
  • The price cut validates the pricing pressure Novo already flagged in its 2026 guidance of -5% to -13% sales growth.
Full Analysis
Novo Nordisk (NVO) shares have plummeted approximately 22% in the past week and 56% over the last year, trading near their 52-week low of roughly $39.63. This significant decline follows two major negative catalysts: a clinical trial failure for its CagriSema drug candidate and a strategic decision to cut prices on its flagship GLP-1 medications. On February 23, the REDEFINE-4 trial results revealed that Novo's CagriSema achieved only 23% average body weight loss compared to Eli Lilly's Zepbound, which saw 25.5%. This performance gap triggered a downgrade from JPMorgan to Neutral and reduced sales forecasts by analysts at Deutsche Bank and Kepler Cheuvreux, with the 12-month average price target now sitting at $54.25. Simultaneously, Novo announced it will slash list prices for Ozempic, Rybelsus, and Wegovy to $675/month effective January 1, 2027, down from Wegovy's current price of roughly $1,349/month. While this move addresses high cost barriers identified in consumer surveys, it validates the pricing pressure Novo had already flagged in its 2026 guidance, which projected sales growth between -5% and -13%. Despite these headwinds, the company recently received EU approval for a higher-dose Wegovy formulation showing superior efficacy, and early scripts for the oral pill formulation have grown by 12% week-over-week. The stock currently trades at 13x trailing earnings as investors debate whether the valuation reflects a durable competitive shift or a temporary overreaction to recent trial misses.